4//SEC Filing
GENZYME CORP 4
Accession 0001225208-11-011386
CIK 0000732485operating
Filed
Apr 5, 8:00 PM ET
Accepted
Apr 6, 12:59 PM ET
Size
15.0 KB
Accession
0001225208-11-011386
Insider Transaction Report
Form 4
GENZYME CORPGENZ
WHITWORTH RALPH V
Director
Transactions
- Exercise/Conversion
Genzyme common stock (GENZ)
2011-04-04+2,375→ 4,750 total - Disposition to Issuer
Stock Option (right to buy)
2011-04-04$51.52/sh−7,125$367,080→ 0 totalExercise: $52.66From: 2010-06-16Exp: 2020-04-14→ Genzyme common stock (GENZ) (7,125 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-04-04$52.66/sh−7,125$375,203→ 0 totalExercise: $51.52From: 2011-06-16Exp: 2020-06-16→ Genzyme common stock (GENZ) (7,125 underlying) - Disposition to Issuer
Genzyme common stock (GENZ)
2011-04-04$74.00/sh−2,375$175,750→ 2,375 total - Disposition from Tender
Genzyme common stock (GENZ)
2011-04-04$74.00/sh−10,606,248$784,862,352→ 0 total(indirect: see footnotes (1) and (2)) - Exercise/Conversion
Restricted Stock Units
2011-04-04−2,375→ 0 totalExercise: $0.00From: 2011-06-16→ Genzyme common stock (GENZ) (2,375 underlying)
Footnotes (4)
- [F1]The reporting person is one of the Principals of Relational Investors LLC ("RILLC"). RILLC is the record owner of 100 shares and sole general partner, or the sole managing member of the general partner, of Relational Investors, L.P., Relational Fund Partners, L.P., Relational Coast Partners, L.P., RH Fund 1, L.P., RH Fund 6, L.P., Relational Investors VIII, L.P., Relational Investors IX, L.P., Relational Investors X, L.P., Relational Investors XV, L.P., Relational Investors XVI, L.P., Relational Investors XX, L.P., Relational Investors XXII, L.P., Relational Investors XXIII, L.P., and Relational Investors Alpha Fund I, L.P.
- [F2]The Limited Partnerships in footnote 1 own a total of 7,963,166 shares. An additional 2,234,482 shares are held in accounts managed by RILLC and an additional 408,500 shares are held through co-investment arrangements with certain entities listed in footnote 1. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F3]The vested restricted stock units were scheduled to vest on the date of the 2011 annual meeting of shareholders.
- [F4]This option, which provided for vesting at the next annual meeting of shareholders, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option.
Documents
Issuer
GENZYME CORP
CIK 0000732485
Entity typeoperating
IncorporatedMA
Related Parties
1- filerCIK 0000732485
Filing Metadata
- Form type
- 4
- Filed
- Apr 5, 8:00 PM ET
- Accepted
- Apr 6, 12:59 PM ET
- Size
- 15.0 KB